Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $5.00 Consensus Price Target from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has received a consensus recommendation of “Hold” from the six research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $5.00.

A number of research firms have recently weighed in on ZNTL. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a report on Wednesday, October 8th. Morgan Stanley cut their target price on Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 12th. Wedbush reissued a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Tuesday, November 11th. Wall Street Zen raised Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price objective on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th.

Insider Buying and Selling

In related news, major shareholder Group Walters acquired 6,459,973 shares of the firm’s stock in a transaction dated Wednesday, December 31st. The stock was acquired at an average cost of $1.20 per share, for a total transaction of $7,751,967.60. Following the completion of the acquisition, the insider directly owned 13,509,973 shares of the company’s stock, valued at approximately $16,211,967.60. The trade was a 91.63% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Matrix Capital Management Comp sold 7,500,000 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $1.33, for a total value of $9,975,000.00. Following the sale, the insider directly owned 6,459,973 shares in the company, valued at approximately $8,591,764.09. The trade was a 53.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.90% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Tybourne Capital Management HK Ltd. boosted its position in shares of Zentalis Pharmaceuticals by 53.7% during the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock valued at $1,715,000 after purchasing an additional 516,666 shares in the last quarter. Acadian Asset Management LLC lifted its stake in Zentalis Pharmaceuticals by 4.7% during the second quarter. Acadian Asset Management LLC now owns 2,799,020 shares of the company’s stock valued at $3,241,000 after purchasing an additional 124,985 shares during the last quarter. Savant Capital LLC bought a new stake in Zentalis Pharmaceuticals during the second quarter worth approximately $59,000. Public Employees Retirement System of Ohio grew its position in Zentalis Pharmaceuticals by 351.7% in the second quarter. Public Employees Retirement System of Ohio now owns 36,700 shares of the company’s stock worth $43,000 after buying an additional 28,576 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Zentalis Pharmaceuticals in the second quarter valued at $38,000.

Zentalis Pharmaceuticals Stock Performance

ZNTL stock opened at $2.43 on Wednesday. Zentalis Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $3.95. The stock has a market capitalization of $175.57 million, a price-to-earnings ratio of -1.17 and a beta of 1.72. The stock’s fifty day moving average is $1.97 and its two-hundred day moving average is $1.68.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.12. As a group, analysts predict that Zentalis Pharmaceuticals will post -2.42 EPS for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.